IBRX's Anktiva fueled a 700% revenue surge in 2025, but can repeat prescriptions, global expansion and BCG shortages sustain momentum into 2026?

Tokyo BCG is not inferior to TICE, and may help ease the BCG shortage. For treatment of high-grade (HG) non-muscle invasive bladder cancer (NMIBC), the Bacillus Calmette-Guérin (BCG) strain Tokyo-172 ...

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS with or without papillary tumors. FDA interactions centered on updated ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has recommended granting a conditional marketing ...

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) ...

Trimodal therapy versus radical cystectomy in muscle-invasive bladder cancer: The overlooked influence of informative censoring—A systematic review and meta-analysis. This is an ASCO Meeting Abstract ...

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

Shares of ImmunityBio, Inc. IBRX soared 41.9% on Wednesday after the company announced that the European Commission (EC) has granted conditional marketing authorization for Anktiva (nogapendekin alfa ...